Small molecule inhibition of the CP is used to treat hematological cancers and an inhibitor of the CP variant immunoproteasome (iP) present in hematopoietic cells or following pro-inflammatory signaling is used against autoimmune inflammatory myopathies. Here, CP is linked to hematopoietic and lymphoid cell neoplasm.